A pathobiology window in the “T-cell world”
Chairman: S.A. Pileri
The last new entities from the ICC
E.S. JaffeMouse models
G.G.A. InghiramiStandard treatment in front-line
Chairman: P. Corradini
How I treat:
ATLL
K. TsukasakiNK/T-cell lymphoma
W.S. KimBreast associated
H.M. PrinceT-PLL
M. HerlingPathology of PTCL in the molecular era
Chairman: S.A. Pileri
Targeting the PTCL Epigenome
Chairman: O.A. O‘Connor
Two intriguing monoclonal antibodies
Chairmen: F. Onida, N. Pimpinelli
Brentuximab vedotin in:
PTCL
B. ProCTCL
H.M. PrinceMogamulizumab in:
CTCL
Y.H. KimImmunotherapy role for T-cell lymphoma
Chairman: P.L. Zinzani
Pembrolizumab in NK/T-cell lymphoma
Y.L. KwongPembrolizumab in PTCL and in CTCL
S.K. BartaTislelizumab
Y.L. KwongAFM-13
W.S. KimTargeting CD47 in PTCL
S. JainTargeting CD47 in CTCL
O. AkilovCTCL: morphology, pathobiology and prognostic models
Chairmen: E. Berti, M. Paulli
MicroRNAs
N. OdumPrognostic models
J. ScarisbrickThe new frontier: CAR-T
Chairman: P.L. Zinzani
CAR-T cell targeting TRBC1 positive T-cell lymphoma
K. CwynarskiEmerging drugs
Chairman: P. Quaglino